|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review, therefore, addresses the role of selective CDK4/6 inhibitors in advanced or metastatic breast cancer with a specific focus on ribociclib.
|
29263697 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CDK4/6 inhibitors, including palbociclib (PD0332991), ribociclib (LEE011) and abemaciclib (LY2835219), have been approved by the US Food and Drug Administration (FDA) for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
|
31632494 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article we will compare and contrast three CDK4/6 inhibitors - palbociclib, ribociclib and abemaciclib - that have received regulatory approval for the treatment of metastatic breast cancer.
|
29935901 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy.
|
30523750 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings suggest that while <i>FGFR1</i> amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, mTOR inhibitors might have a unique therapeutic role in the treatment of patients with ER<sup>+</sup>/FGFR1<sup>+</sup> MBC.
|
31371343 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the pharmacologic costs of CDK4/6 inhibitors (palbociclib and ribociclib) in hormone receptor-positive (HR<sup>+</sup>)/human epidermal receptor 2-negative (HER2<sup>-</sup>) advanced or metastatic breast cancer (BC).
|
30858036 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
The highly selective oral CDK4/6 inhibitors have been tested in combination with endocrine therapy in Phase III studies in metastatic breast cancer.
|
28741274 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC).
|
30118901 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mTOR/CDK4/6 inhibitors may influence the development of edema, which may cause or exacerbate progression of BCRL in patients with MBC.
|
30919166 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: All three CDK4/6 inhibitors have shown remarkable efficacy when added to endocrine therapy in the treatment of HR+/HER2- MBC with consistent improvements in progression-free survival across all phase III trials.
|
30360668 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
|
30685576 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors in combination with endocrine therapy have significantly improved the progression-free survival of patients with ER+/HER2- metastatic breast cancer.
|
27564114 |
2016 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase III randomized clinical trials have proven that CDK4/6 inhibitors (CDK4/6i) in combination with several endocrine agents improve treatment efficacy over endocrine agents alone for hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC).
|
30631751 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are available for women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
|
31369120 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer.
|
28872469 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of CDK4/6 inhibitors in clinics is becoming common for patients with HR+/HER2- metastatic breast cancer and will certainly increase in the near future.
|
29234249 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibition is a new and promising target for patients with hormone-receptor-positive MBC.
|
28657360 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Standard treatment for estrogen receptor-positive metastatic breast cancer involves antiestrogen therapy used alone or in combination with inhibitors of CDK4/6 or mTOR; this approach works mechanistically by eliciting and reinforcing cell-cycle arrest.
|
30824486 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: CDK4/6 inhibition represents a promising treatment option for patients with HR+ metastatic breast cancer.
|
29457921 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib, a CDK4-6 inhibitor, combined with endocrine therapy (ET) is a new standard of treatment for Hormone Receptor-positive Metastatic Breast Cancer.
|
29247442 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the early toxicity of concurrent use of radiotherapy in association with CDK4/6 inhibitors (palbociclib or ribociclib) in patients with hormone-receptors positive metastatic breast cancer.
|
31100573 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer.
|
26947331 |
2016 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
|
29236940 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine-therapy have emerged as an important regimen of care for estrogen receptor (ER)-positive metastatic breast cancer, although identifying predictive biomarkers remains a challenge.
|
30692100 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib (PD-332991) specifically inhibits CDK4/6, and it has been approved for use in metastatic breast cancer in combination with letrazole.
|
28349562 |
2017 |